[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urticaria\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urticaria":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,56,84,125,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":4},"100629926","a-randomised-controlled-trial-of-eprom-guided-flexible-scheduling-in-dermatology-100629926",false,"NCT07481019","A Randomised Controlled Trial of ePROM-Guided Flexible Scheduling in Dermatology","Inclusion Criteria:\n\n* Dermatology outpatients otherwise due for a follow-up appointment within six months.\n* Ability to independently navigate and complete ePROMs.\n* Ability to provide informed consent (including parental consent for minors).\n\nExclusion Criteria:\n\n* Patients who require fixed or scheduled in-person visits, including those needing skin cancer surveillance, bedside procedures (e.g., liquid nitrogen therapy), surgical interventions, or routine blood tests for immunosuppressive therapy.","ALL","16 Years",{"count":18,"type":19},250,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this clinical trial is to evaluate whether an electronic patient-reported outcome measure (ePROM)-guided flexible scheduling system can improve outpatient clinic resource utilisation in patients attending dermatology outpatient clinics for routine follow-up. The main questions it aims to answer are:\n\n* Does the intervention reduce the number of actualised outpatient visits over 12 months compared with standard fixed scheduling?\n* Does the intervention group achieve higher adherence to monthly ePROM monitoring, as measured by the proportion of completed ePROM submissions?",[25,26,27,28,29],"Chronic Dermatological Conditions","Eczema","Urticaria","Psoriasis","Acne",[31,32,33,34,35,36,37,38,39,40,41,42,43],"dermatology","flexible scheduling","patient initiated follow up","electronic patient-reported outcomes","ePROMs","Bayesian decision support","outpatient care","health services research","randomised controlled trial","implementation science","healthcare utilisation","appointment no-shows","value-based care","NOT_YET_RECRUITING","2026-06-29",{"date":47,"type":48},"2026-07-01","ACTUAL",{"date":50,"type":19},"2026-09",{"date":52,"type":19},"2029-12",{"name":54,"class":55},"National University Hospital, Singapore","OTHER",{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":20,"phases":65,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},"100570057","use-of-a-digital-psychotherapeutic-app-to-reduce-symptom-burden-in-dermatology-patients-100570057","NCT06702293","Use of a Digital Psychotherapeutic App to Reduce Symptom Burden in Dermatology Patients","Development and Testing of a Digital Psychological Tool to Improve Symptom Burden in Dermatology Patients","Inclusion Criteria:\n\n* Patients with psoriasis, eczema or chronic urticaria diagnosed by a dermatologist\n* Aged 16 or older\n* Peak pruritus intensity of 4 or more on a 11-point numerical rating scale (0-10, with 10 representing worst itch)\n* Able to engage with a mobile application in the English language\n\nExclusion Criteria:\n\n* Patients with active psychiatric symptoms (e.g. active suicidal ideation, psychosis, delusions)\n* Patients with unstable psychiatric condition, characterized by\n\n  o Hospital inpatient admission for a psychiatric condition or initiation of a psychotropic medication in the prior 3 months\n* Patients with unstable dermatological condition, characterized by\n\n  * Recent flare of the skin condition within the last 2 weeks, including diagnosis of a flare by a doctor, use of systemic steroids, oral antibiotics, wet wrap rescue therapy, oral antivirals, or increase in frequency of phototherapy or dose of systemic medications for the dermatological condition within the last 2 weeks OR\n  * Any of the following within 3 months\n\n    * inpatient admission for a dermatological condition\n    * Initiation of phototherapy\n    * Initiation of systemic therapy (conventional immunosuppressive agent, biologics, JAK inhibitors) within the last 3 months.",{"count":64,"type":19},690,[22],"Skin diseases, despite low mortality, significantly impair quality of life. This randomised controlled trial evaluates the efficacy of a digital toolkit comprising psychotherapeutic strategies in reducing QoL burden in patients with chronic inflammatory skin conditions. This toolkit is hosted on a mobile application and will be used by study participants randomised to the intervention arm over the 32 week study period.",[26,28,27],[69,70,71,72,73,74,75],"digital health","eczema","psoriasis","urticaria","healthservices research","digital","mental health","RECRUITING",{"date":47,"type":48},{"date":79,"type":48},"2026-02-23",{"date":81,"type":19},"2029-07",{"name":54,"class":55},1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":15,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":20,"phases":96,"briefSummary":97,"conditions":98,"keywords":105,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100637488","efficacy-and-safety-of-ha35-gel-for-ultra-rapid-skin-pruritus-relief-100637488","NCT07580911","Efficacy and Safety of HA35 Gel for Ultra-Rapid Skin Pruritus Relief","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate Efficacy and Safety of Topical 10% 35 kDa Hyaluronan (HA35) Gel for Ultra-Rapid Relief of Diverse Etiology Skin Pruritus","HA35-ITCH","Inclusion Criteria:\n\n* Age 18-65 years, male or female\n* Moderate-to-severe skin pruritus (NRS ≥6) due to eczema, neurodermatitis, insect bites, urticaria, or postoperative wound itch\n* Able to understand and complete NRS assessments independently\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Topical corticosteroid\u002Fantihistamine use within 2 weeks\n* Infected, broken, or exudative skin lesions at the application site\n* Known hypersensitivity to hyaluronan or gel components\n* Severe systemic disease or immune dysfunction\n* Pregnant or lactating women","18 Years","65 Years",{"count":95,"type":19},30,[22],"This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel for ultra-rapid relief of moderate-to-severe skin pruritus from diverse etiologies (eczema, neurodermatitis, insect bites, urticaria, postoperative wound itch). Eligible participants will receive a single topical application of HA35 gel. The primary objective is to assess pruritus relief at 10 seconds, 45 minutes, 8 hours, 12 hours, and 24 hours post-application. Safety and local skin tolerability will be evaluated throughout the observation period. This is a minimal-risk, non-pharmacological, non-invasive intervention.",[99,100,101,102,103,27,104],"Skin Pruritus","Itch","Eczema Itch","Neurodermatitis","Insect Bite Itch","Postoperative Wound Pruritus",[106,107,108,109,99,110,111,112,113,114],"Hyaluronan","35 kDa Hyaluronan","HA35","Topical Gel","Itch Relief","Ultra-Rapid Relief","Anti-Pruritus","Non-Steroidal","Pilot Clinical Study","2026-05-05",{"date":117,"type":48},"2026-05-12",{"date":119,"type":19},"2026-06-20",{"date":121,"type":19},"2026-08-20",{"name":123,"class":124},"Nakhia Impex LLC","INDUSTRY",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":132,"sex":15,"minAge":92,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":20,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":4},"100587165","a-clinical-study-to-assess-the-safety-and-effectiveness-of-utixira-lotion-and-utixira-tablet-in-healthy-adult-human-subjects-with-dry-or-sensitive-skin-prone-to-mild-to-moderate-pruritus-and-urticaria-100587165","NCT06924840","A Clinical Study to Assess the Safety and Effectiveness of Utixira Lotion and Utixira Tablet in Healthy Adult Human Subjects With Dry or Sensitive Skin Prone to Mild to Moderate Pruritus and Urticaria","A Clinical Evaluation of the Safety, In-Use Tolerability, and Efficacy of the Utixira Lotion and Utixira Tablet Combination Regimen in Healthy Adults With Dry, Sensitive Skin Prone to Mild to Moderate Pruritus and Urticaria","Inclusion Criteria:\n\n* Age: 18 to 55 years (both inclusive) at the time of consent.\n* Sex: Healthy male and non-pregnant\u002Fnon-lactating females.\n* Females of childbearing potential must have a self-reported negative pregnancy test.\n* Subject are generally in good health.\n* Subject with dry or sensitive skin at a time of screening. (Dermatological Assessment)\n* Subjects having pruritus or urticaria at a time of screening.\n* Subjects application site must be free of cuts, tattoos, scratches, abrasions, scars, uneven skin tone, sunburn, excessive tan, excessive hair or open wounds.\n* Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.\n* If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device\u002Finjection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.\n* Subjects are willing to give written informed consent and are willing to come for regular follow up.\n* Subjects who commit not to use medicated skincare product other than the test product for the entire duration of the study.\n* Subject who have not participated in a similar investigation in the past three months.\n* Willing to use test product throughout the study period.\n\nExclusion Criteria:\n\n* History of any dermatological condition of the skin diseases.\n* Subject with present condition of allergic response to any cosmetic product.\n* Subject having allergic response to the ink.\n* Presence of any broken, chapped, cut, irritated, or scraped skin at the application site.\n* Subjects under chronic medication (e.g. aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy etc.) that might influence the outcome of the study.\n* Subject having acne of severe incidence (presence of nodules, cysts or numerous pustules) which requires pharmaceutical or cosmeceuticals, herbal treatment.\n\nSubjects who have applied topical treatment for at least 4 weeks and any systemic treatment for at least 3 months, before they participated in the study.\n\n* History of alcohol or drug addiction.\n* Subjects using other marketed products during the study period.\n* Any other condition which could warrant exclusion from the study, as per the dermatologist's\u002Finvestigator's discretion.\n* Pregnant or breastfeeding or planning to become pregnant during the study period.\n* History of chronic illness which may influence the cutaneous state.\n* Subjects participating in other similar cosmetics, devices or therapeutic trials or skincare products within the last four weeks.",true,"55 Years",{"count":135,"type":19},32,[22],"This exploratory, prospective, open-label, single-centre, safety, efficacy and in-use tolerability study of the Utixira Lotion + Utixira Lotion as regimen in healthy adult human subjects with dry or sensitive skin and prone to mild to moderate pruritus or urticaria",[139,27,140,141],"Dry Skin","Pruritus","Sensitive","2025-04-15",{"date":144,"type":48},"2025-04-18",{"date":146,"type":19},"2025-05-15",{"date":148,"type":19},"2025-06-15",{"name":150,"class":55},"SAVA Healthcare Limited",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":15,"minAge":157,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":160,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":4},"100582163","survey-on-the-characteristics-of-traditional-medicine-syndromes-in-urticaria-patients-at-le-van-thinh-hospital-100582163","NCT06859736","Survey on the Characteristics of Traditional Medicine Syndromes in Urticaria Patients At Le Van Thinh Hospital","Inclusion Criteria:\n\n* Patients aged 15 years or older.\n* Diagnosed with acute or chronic urticaria based on modern medical criteria.\n* Willing to participate and provide informed consent.\n\nExclusion Criteria:\n\n* Patients with other dermatological conditions that may interfere with the diagnosis of urticaria.\n* Patients currently using medications that may alter symptom presentation (e.g., antihistamines, corticosteroids, immunosuppressants).\n* Patients who refuse to participate in the study","15 Years",{"count":159,"type":19},150,"OBSERVATIONAL","This study aims to investigate the characteristics of Traditional Medicine (TM) syndromes in urticaria patients at Le Van Thinh Hospital. Urticaria is a common dermatological condition that significantly impacts patients' quality of life. However, there is limited research on TM syndrome classification in this patient group. The study will collect data on symptoms, TM syndromes, and disease severity to determine common syndromes and their associations with clinical manifestations.\n\nThe study will be conducted as a cross-sectional, observational study with an estimated 200 participants. Eligible patients are those aged 18 years or older, diagnosed with acute or chronic urticaria, and willing to participate. The primary outcomes include the prevalence of TM syndromes, itching severity measured by the Visual Analogue Scale (VAS), and the correlation between TM syndromes and itching severity.\n\nThe study is approved by the Institutional Review Board (IRB) of the University of Medicine and Pharmacy at Ho Chi Minh City and will be conducted from December 2024 to April 2025 at Le Van Thinh Hospital, Vietnam.",[27],"2025-02-28",{"date":165,"type":48},"2025-03-05",{"date":167,"type":19},"2025-03-01",{"date":169,"type":19},"2025-09-01",{"name":171,"class":55},"Do Thanh Sang"]